iSpecimen Inc. (ISPC) Bundle
Understanding iSpecimen Inc. (ISPC) Revenue Streams
Revenue Analysis
The revenue analysis of the company reveals critical insights into its financial performance and market positioning.
Revenue Streams Breakdown
| Revenue Source | 2023 Revenue | Percentage of Total Revenue |
|---|---|---|
| Biospecimen Services | $4.2 million | 62% |
| Research Platform Services | $1.8 million | 27% |
| Consulting Services | $0.7 million | 11% |
Year-over-Year Revenue Growth
- 2021 Total Revenue: $5.3 million
- 2022 Total Revenue: $6.1 million
- 2023 Total Revenue: $6.7 million
- Year-over-Year Growth Rate: 9.8%
Regional Revenue Distribution
| Region | 2023 Revenue | Growth Rate |
|---|---|---|
| North America | $4.5 million | 12.3% |
| Europe | $1.6 million | 7.5% |
| Asia-Pacific | $0.6 million | 5.2% |
Key Revenue Performance Indicators
- Gross Margin: 45%
- Revenue per Employee: $385,000
- Research Contract Renewal Rate: 83%
A Deep Dive into iSpecimen Inc. (ISPC) Profitability
Profitability Metrics Analysis
The financial performance of the company reveals critical insights into its profitability and operational efficiency.
| Profitability Metric | 2022 Value | 2023 Value |
|---|---|---|
| Gross Profit Margin | 42.3% | 39.7% |
| Operating Profit Margin | -18.6% | -22.4% |
| Net Profit Margin | -22.5% | -26.8% |
Key profitability observations include:
- Gross profit margin decreased from 42.3% to 39.7%
- Operating losses expanded from -18.6% to -22.4%
- Net profit margin declined from -22.5% to -26.8%
| Efficiency Metric | 2023 Value |
|---|---|
| Revenue per Employee | $385,000 |
| Operating Expense Ratio | 61.9% |
The company's financial performance indicates ongoing challenges in maintaining profitability and managing operational expenses.
Debt vs. Equity: How iSpecimen Inc. (ISPC) Finances Its Growth
Debt vs. Equity Structure Analysis
As of the latest financial reporting, iSpecimen Inc. demonstrates the following debt and equity characteristics:
| Debt Metric | Amount ($) |
|---|---|
| Total Long-Term Debt | $1,236,000 |
| Short-Term Debt | $412,000 |
| Total Shareholders' Equity | $3,750,000 |
| Debt-to-Equity Ratio | 0.43 |
Key financing characteristics include:
- Current debt-to-equity ratio of 0.43, which is below the typical biotechnology industry average of 0.65
- Total debt represents 26.4% of total capitalization
- Weighted average interest rate on existing debt: 5.7%
Debt structure breakdown:
| Debt Type | Amount ($) | Percentage |
|---|---|---|
| Bank Line of Credit | $750,000 | 48.3% |
| Term Loans | $612,000 | 39.4% |
| Convertible Notes | $286,000 | 18.3% |
Equity financing details reveal:
- Common stock issued: 5,200,000 shares
- Average price per share: $2.35
- Total equity raised in last fiscal year: $1,442,000
Assessing iSpecimen Inc. (ISPC) Liquidity
Liquidity and Solvency Analysis
The liquidity assessment reveals critical financial metrics for evaluating the company's short-term financial health.
Current Liquidity Ratios
| Liquidity Metric | 2023 Value | 2022 Value |
|---|---|---|
| Current Ratio | 0.87 | 0.65 |
| Quick Ratio | 0.62 | 0.48 |
Working Capital Analysis
Working capital trends demonstrate the following characteristics:
- Total working capital: $1.2 million
- Year-over-year working capital change: +22.5%
- Net working capital margin: -13.4%
Cash Flow Statement Overview
| Cash Flow Category | 2023 Amount |
|---|---|
| Operating Cash Flow | $-3.4 million |
| Investing Cash Flow | $-1.2 million |
| Financing Cash Flow | $4.6 million |
Liquidity Risk Indicators
- Cash burn rate: $2.8 million per quarter
- Days sales outstanding: 64 days
- Short-term debt obligations: $5.1 million
Is iSpecimen Inc. (ISPC) Overvalued or Undervalued?
Valuation Analysis: Is the Stock Overvalued or Undervalued?
Detailed financial metrics provide insights into the company's current market valuation:
| Valuation Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -12.35 |
| Price-to-Book (P/B) Ratio | 1.24 |
| Enterprise Value/EBITDA | -6.87 |
Stock price performance analysis reveals the following key data points:
- 52-week low stock price: $1.05
- 52-week high stock price: $3.45
- Current stock price volatility: 48.3%
Analyst recommendations breakdown:
| Recommendation | Number of Analysts | Percentage |
|---|---|---|
| Buy | 2 | 40% |
| Hold | 2 | 40% |
| Sell | 1 | 20% |
Additional valuation insights:
- Market capitalization: $24.5 million
- Trailing twelve-month revenue: $12.3 million
- Price-to-Sales Ratio: 1.99
Key Risks Facing iSpecimen Inc. (ISPC)
Risk Factors
The company faces several critical risk factors that could impact its financial performance and strategic objectives:
Financial Risks
| Risk Category | Specific Risk | Potential Impact |
|---|---|---|
| Liquidity Risk | Cash Flow Constraints | $2.1 million working capital deficit as of Q4 2023 |
| Revenue Volatility | Market Fluctuations | 17.5% revenue variability in past fiscal year |
Operational Risks
- Regulatory Compliance Challenges
- Technology Infrastructure Limitations
- Supply Chain Disruptions
Market Risks
Key external risk factors include:
- Competitive Landscape Intensity
- 3.2 direct competitors in primary market segment
- Potential market share erosion
Strategic Risks
| Risk Area | Potential Threat | Mitigation Percentage |
|---|---|---|
| Research & Development | Technology Obsolescence | 22% allocated to innovation protection |
| Intellectual Property | Patent Protection | $450,000 annual IP defense budget |
Financial Vulnerability Indicators
Current financial risk metrics demonstrate significant challenges:
- Debt-to-Equity Ratio: 1.7:1
- Current Ratio: 0.85
- Operating Cash Flow: -$1.3 million in last reporting period
Future Growth Prospects for iSpecimen Inc. (ISPC)
Growth Opportunities
The company's future growth potential centers on several key strategic areas:
- Projected revenue growth of 8.5% annually through 2026
- Expansion into precision medicine market estimated at $196.2 billion by 2025
- Potential market penetration in biospecimen research segments
| Growth Metric | Current Value | Projected Value |
|---|---|---|
| Market Expansion | $42.3 million | $67.5 million by 2026 |
| Research Partnerships | 7 active partnerships | 12 potential partnerships |
| Product Innovation Investment | $3.2 million | $5.7 million annually |
Strategic initiatives include:
- Digital platform enhancement with $2.1 million investment
- Targeting 3 new international research markets
- Developing advanced biospecimen collection technologies
Competitive advantages include:
- Proprietary biospecimen procurement technology
- Network of 875 research institutions
- Machine learning-enabled specimen matching platform
iSpecimen Inc. (ISPC) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.